Thematic Take

Powered by

Cyrus Mewawalla, Head of Thematic Intelligence, GlobalData

Foreword: Adequate AI is already here

At GlobalData, we define a theme as any issue that keeps a business leader awake at night.

Companies are impacted by multiple themes that frequently conflict with one another. What is needed is an effective methodology that reflects, understands, and reconciles these conflicts. Our thematic research ecosystem is a single, integrated global research platform that provides an easy-to-use framework for tracking all themes across all companies in all sectors.

Viewing the world’s data by themes makes it easier to make critical decisions. Companies that invest in the right themes become success stories. Those that miss the essential themes in their industry end up as failures.

For decades artificial intelligence (AI) has primarily been the territory of university and corporate R&D labs. Recent progress in machine learning (ML) on the back of improved algorithms (e.g., OpenAI’s GPT-4) and increasing computing power have made it possible for AI to solve real-life problems. In the coming decade, the country that emerges on top in AI will lead the Fourth Industrial Revolution.

Despite the hype, artificial general intelligence (AGI), or the ability of machines to do anything that a human can and possess consciousness, is still decades away. However, ‘good enough’ AI is already here, capable of interacting with humans, motion, and making decisions. For example, ChatGPT can write original prose and chat with human fluency, DeepMind's algorithms can beat the best human chess players, and Boston Dynamics' Atlas robots can somersault. If this evolution continues, it could upend the labor-based capitalist economic model.

Go to article: Home | Clinics ration supplies as cancer drug shortages proliferateGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: Owen Mumford Company InsightGo to article: Owen MumfordGo to article: In DepthGo to article: Clinics ration supplies as cancer drug shortages proliferateGo to article: Asian countries prioritise rare disease market access amid stark disparities Go to article: Supercritical fluids advance sterilisation tech in pharmaGo to article: Fighting AMR with a value and subscription modelGo to article: Q&A: How can the US maintain access to essential drugs?Go to article: Inflation reduction act boosts biologic VC financing over small moleculesGo to article: NiproGo to article: Thematic TakeGo to article: Thematic Take: contentsGo to article: ForewordGo to article: An introduction to artificial intelligenceGo to article: A history of artificial intelligenceGo to article: The impact of artificial intelligence on the pharmaceutical sectorGo to article: Case studies: artificial intelligence in the pharmaceutical industryGo to article: Latest news: artificial intelligence in pharmaGo to article: Q&A with GlobalData thematic analystGo to article: Rx Machina: how AI is transforming pharma sales Go to article: Artificial intelligence innovation: leading companies in in-silico drug discovery Go to article: Leading clinical trials companies in the artificial intelligence theme Go to article: Deal activity related to artificial intelligence in the pharmaceutical industry since 2020Go to article: Artificial intelligence hiring trends in the global pharmaceutical industry since 2020Go to article: Artificial intelligence patent applications in the global pharmaceutical industry since 2020Go to article: Mentions of artificial intelligence in pharmaceutical industry company filings since 2020Go to article: GlobalData Thematic IntelligenceGo to article: Sponsored SupplementsGo to article: ListingsGo to article: EventsGo to article: Event: 10th Annual Outsourcing In Clinical Trials UK And Ireland 2023Go to article: AwardsGo to article: Buyer's GuidesGo to article: Next issue